• Logo
  • SBMUJournals

Diagnostic Value of Plasma Pentraxin3- Level For Diagnosis of Erectile Dysfunction

Ali Erhan Eren, Ahmet Re?it Ersay, Emrah Demirci, Cabir Alan, Gökhan Basturk



Purpose: Erectile dysfunction (ED) is a sexual dysfunction described as the inability to develop or maintain an erection of the penis adequate for sexual intercourse, and its prevalence increases with age. Seen as a common sexual disorder worldwide, organic causes are the underlying reason for 80 percent of ED cases, with the most characteristic pathology responsible for organic ED being atherosclerosis. This study investigates the diagnostic value of plasma PTX-3 levels in arterial ED.
Materials and Methods: This study included a total of 45 patients who were admitted to the urology and cardiology
outpatient clinics of the Medical Faculty of Canakkale Onsekiz Mart University (COMU) and consented to participate in this study. Patients were categorized into three equal groups in number: (1) patients with ED diagnosed with coronary artery disease (CAD) (15 patients in total); (2) patients with ED not having coronary artery disease or any other equivalent diseases (diabetes mellitus, hypertension and hyperlipidemia) (15 patients in total);
and (3) ordinary patients with no ED (15 patients in total). An interview was conducted at the andrology polyclinic with each patient in order to ascertain detailed information on their medical and sexual history and on demographic characteristics. All patients were also administered the International Index of Erectile Function (IIEF) questionnaire.
Result: The findings from this study investigating the diagnostic value of plasma PTX-3 levels in ED were statistically significant for two comparisons: the differences between the peripheral blood and cavernous blood values of the patient groups (group 1 and 2) and the control group (group 3), and the differences between the peripheral blood and cavernous blood values of group 2 (patients with ED who do not have CAD) and the control group (group 3).
Conclusion: As PTX-3 is more specific than the formerly recognized biochemical markers in endothelial dysfunction, it can be used in the diagnosis of vascular originated ED.


NIH. Impotence. JAMA 1993; 270:83-90.

Montague DK, Barada JH, Belker AM, et al. Clinical guidelines panel on erectile dysfunction: summary report on the treatment

of organic erectile dysfunction. The American Urological Association. J Urol 1996;156:2007-11.

Laumann EO, Paik A, Rosen R:Sexual dysfunction in the United States: prevelance and predictors. JAMA 1999; 21: 537- 44.

Banet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North America 1995; 1995:699-709.

Seth EL, Arnold M, George J, Christ. A review of erectile dysfunction. New insights and more questions. The J. Urology 1993; 149:1246-55.

Sullivan ME, Keoghane SR, Miller MA. Vascular risk factors and erectile dysfunction. BJU Int 2001; 87:838-45.

Ross R. Atherosclerosis; an inflammatory disease. N Engl J Med 1999; 340: 115-26.

Kinlay S, Ganz P. Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol 1997;

: 11- 6.

Maas R, Schwedhelm E, Albsmeier J, Boger RH. The pathophysiology of Erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med

; 7: 213- 25.

Ganz P. Erectile dysfunction: Pathophysiologic mechanisms pointing to underlying cardiovascular disease. Am J Cardiol 1996;

(suppl): 8M- 12M.

Dayan L, Greunwald I, Vardi Y, Jacob G. A new clinical method for the assessment of penile endothelial function using the flow mediated dilation with plethysmography technique. J Urol 2005; 173:1268-72.

Sullivan ME, Thompson CS, Dashwood MR, et al. Nitric oxide and penile erection: is erectile dysfunction another manifestation

of vascular disease? Cardiovasc Res 1999;43:658-65.

Billups KL. Erectile dysfunction as an early sign of cardiovasculsar disease. International Journal of Impotence Research 2005; 17:19-24.

Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity,inflammation, matrix deposition, and female fertility. Annu Rev Immunol.


Steel DM, Whitehead AS. The ana acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today. 1994; 15: 81–8.

Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein

and serum amyloid P component. J Biol Chem. 1997; 272: 32817–23.

Spagnoli LG, Bonanno E, Sangiorgi G, Mauriello A. Role of Inflammation in Atherosclerosis. J Nucl Med 2007;48:1800–15.

Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty RM. In the Elderly, Interleukin-6 Plasma Levels and the −174G>C Polymorphism Are Associated With the Development of Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2002; 22: 2066-71.

Lewis RW. Epidemiology of erectile dysfunction. Urol Clin North Am 2001 May;28(2):209-16

Saygı S, Kırılmaz B, Tengiz İ, Önsel Türk U, Yıldız H, Tüzün N, Alioğlu E, Sönmez Tamer G, Ercan E. Long Pentraxin-3 Measured At Late Phase Associated With GRACE Risk Scores in Patients With Non-ST Elevation Acute Coronary Syndrome and Coronary


Suliman ME, Yilmaz MI, Carrero JJ, et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in

early and advanced chronic kidney disease. Clinical Journal of the American Society of Nephrology. 2008;3:976–85.

Kunes P, Holubcova Z, Kolackova M, Krejsek J. Pentraxin 3(PTX 3): An Endogenous Modulator of the Inflammatory Response. Mediators of Inflammation. 2012;2012:920517

K. Inoue, A. Sugiyama, P. C. Reid et al., “Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 161–167, 2007.

Ustündağ M, Orak M, Güloğlu C, Sayhan MB, Alyan O, Kale E. Comparative diagnostic accuracy of serum levels of neutrophil

activating peptide-2 and pentraxin-3 versus troponin-I in acute coronary syndrome. Anadolu Kardiyol Derg. 2011;11:588–94

Bonacina F, Baragetti A, Catapano AL, Norata GD. Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular

Diseases. Mediators of Inflammation. 2013;2013:725102

Brock G. Diagnosing erectile dysfunction could save your patient’s life.Canadian Urological Association Journal. 2014;8(7-8

Suppl 5):S151-S152.

DOI: http://dx.doi.org/10.22037/uj.v0i0.3989


  • There are currently no refbacks.